MK-507 versus sezolamide. Comparative efficacy of two topically active carbonic anhydrase inhibitors.

Abstract

Topical carbonic anhydrase inhibitors MK-507 and sezolamide hydrochloride (previously known as MK-417) were compared in a double-masked, randomized, placebo-controlled study in 82 patients with bilateral primary open-angle glaucoma or ocular hypertension. MK-507 was given every 8 or 12 hours, sezolamide every 8 hours, or placebo every 8 or 12 hours for 4 days. Both drugs lowered intraocular pressure (IOP) substantially. MK-507 was somewhat more active than sezolamide, with a peak mean IOP reduction of 26.2% for MK-507 versus 22.5% for sezolamide, although the difference between the treatments was not statistically significant. These drugs may have potential in the treatment of glaucoma.

• Authors: E A Lippa, J S Schuman, E J Higginbotham, M A Kass, R N Weinreb, G L Skuta, D L Epstein, B Shaw, D J Holder, D A Deasy
• Journal: Ophthalmology (Ophthalmology) Vol. 98 Issue 3 Pg. 308-12; discussion 312-3 (Mar 1991) ISSN: 0161-6420 [Print] United States
• PMID: 2023750 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Antihypertensive Agents
• Carbonic Anhydrase Inhibitors
• Sulfonamides
• Thiophenes
• dorzolamide
• sezolamide

Topics

• Administration, Topical
• Adult
• Aged
• Aged, 80 and over
• Antihypertensive Agents (therapeutic use)
• Carbonic Anhydrase Inhibitors (therapeutic use)
• Double-Blind Method
• Female
• Glaucoma, Open-Angle (drug therapy)
• Humans
• Intraocular Pressure (drug effects)
• Male
• Middle Aged
• Ocular Hypertension (drug therapy)
• Sulfonamides (therapeutic use)
• Thiophenes (therapeutic use)